• Product NameRecombinant Murine Interleukin-36 beta, 153a.a.
• Host SpeciesEscherichia coli.
• Purification> 97 % by SDS-PAGE and HPLC analyses.
• Biological ActivityFully biologically active when compared to standard. The ED50 as determined by inducing IL-6 secretion in murine NIH/3T3 cells is less than 10 ng/ml, corresponding to a specific activity of > 1.0 x10⁵ IU/mg.
• EndotoxinLess than 1 EU/ug of rMuIL-36β, 153a.a. as determined by LAL method.
• Alternative Names    FIL1 eta, IL-1 eta, IL-1F8, IL-1H2
• UniprotQ9D6Z6
• Gene ID69677
• Calculated MW Approximately 17.4 kDa, a single non-glycosylated polypeptide chain containing 153 amino acids.
• Target Sequence SSQSPRNYRV HDSQQMVWVL TGNTLTAVPA SNNVKPVILS LIACRDTEFQ DVKKGNLVFL GIKNRNLCFC CVEMEGKPTL QLKEVDIMNL YKERKAQKAF LFYHGIEGST SVFQSVLYPG WFIATSSIER QTIILTHQRG KLVNTNFYIE SEK
• Formulation Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4, 5% trehalose.
• Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 ˚C as supplied.- 1 month, 2 to 8 ˚C under sterile conditions after reconstitution.- 3 months, -20 to -70 ˚C under sterile conditions after reconstitution.

Interleukin-36 is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36 beta is reported to be expressed at higher levels in psoriatic plaques than in symptomless psoriatic skin or healthy control skin and it can stimulate production of interleukin-6 and interleukin-8 in synovial fibrobasts, articular chondrocytes and mature adipocytes. IL-36 beta has two isoforms. IL-36β2 contains one potential N-linked glycosylation site in its C-terminus, while IL -36β isoform 1 lacks potential N-linked glycosylation sites and four of the conserved β-strands. Within the IL-1 family, IL-36β/IL-1F8 shares 30 %, 32 %, 37 %, 46 %, 34 %, 45 % and 28 % a.a. sequence identity with IL-1 ra, IL-1β, IL-36Ra/IL-1F5, IL-36α/IL-1F6, IL-37/IL-1F7, IL-36γ/IL-1F9 and IL-1F10, respectively.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting